10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Design of a multifaceted strategy based on automated text messaging in patients with recent heart failure admission

      research-article
      1 , 2 , , 3 , 4 , 2 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 1 , 23 , 23 , 23 ,
      ESC Heart Failure
      John Wiley and Sons Inc.
      Heart failure, Natriuretic peptide, Telemonitoring

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Aims

          To evaluate a telemonitoring strategy based on automated text messaging and telephone support after heart failure (HF) hospitalization.

          Methods and results

          The MESSAGE‐HF study is a prospective multicentre, randomized, nationwide trial enrolling patients from 30 clinics in all regions of Brazil. HF patients with reduced left ventricular ejection fraction (<40%) and access to mobile phones are eligible after an acute decompensated HF hospitalization. Patients meeting eligibility criteria undergo an initial feasibility text messaging assessment and are randomized to usual care or telemonitoring intervention. All patients receive a HF booklet with basic information and recommendations about self‐care. Patients in the intervention group receive four daily short text messages (educational and feedback) during the first 30 days of the protocol to optimize self‐care; the feedback text messages from patients could trigger diuretic adjustments or a telephone call from the healthcare team. After 30 days, the frequency of text messages can be adjusted. Patients are followed up after 30, 90, and 180 days, with final status ascertained at 365 days by telephone. Our primary endpoint is the change in N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) levels after 180 days. Secondary endpoints include changes in NT‐proBNP after 30 days; health‐related quality of life, HF self‐care, and knowledge scales after 30 and 180 days; and a composite outcome of HF hospitalization and cardiovascular death, adjudicated by a blinded and independent committee.

          Conclusions

          The MESSAGE‐HF trial is evaluating an educational and self‐care promotion strategy involving a simple, intensive, and tailored telemonitoring system. If proven effective, it could be applied to a broader population worldwide.

          Related collections

          Most cited references29

          • Record: found
          • Abstract: found
          • Article: not found

          Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial.

          Results of previous studies support the hypothesis that implantable haemodynamic monitoring systems might reduce rates of hospitalisation in patients with heart failure. We undertook a single-blind trial to assess this approach. Patients with New York Heart Association (NYHA) class III heart failure, irrespective of the left ventricular ejection fraction, and a previous hospital admission for heart failure were enrolled in 64 centres in the USA. They were randomly assigned by use of a centralised electronic system to management with a wireless implantable haemodynamic monitoring (W-IHM) system (treatment group) or to a control group for at least 6 months. Only patients were masked to their assignment group. In the treatment group, clinicians used daily measurement of pulmonary artery pressures in addition to standard of care versus standard of care alone in the control group. The primary efficacy endpoint was the rate of heart-failure-related hospitalisations at 6 months. The safety endpoints assessed at 6 months were freedom from device-related or system-related complications (DSRC) and freedom from pressure-sensor failures. All analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00531661. In 6 months, 83 heart-failure-related hospitalisations were reported in the treatment group (n=270) compared with 120 in the control group (n=280; rate 0·31 vs 0·44, hazard ratio [HR] 0·70, 95% CI 0·60-0·84, p<0·0001). During the entire follow-up (mean 15 months [SD 7]), the treatment group had a 39% reduction in heart-failure-related hospitalisation compared with the control group (153 vs 253, HR 0·64, 95% CI 0·55-0·75; p<0·0001). Eight patients had DSRC and overall freedom from DSRC was 98·6% (97·3-99·4) compared with a prespecified performance criterion of 80% (p<0·0001); and overall freedom from pressure-sensor failures was 100% (99·3-100·0). Our results are consistent with, and extend, previous findings by definitively showing a significant and large reduction in hospitalisation for patients with NYHA class III heart failure who were managed with a wireless implantable haemodynamic monitoring system. The addition of information about pulmonary artery pressure to clinical signs and symptoms allows for improved heart failure management. CardioMEMS. Copyright © 2011 Elsevier Ltd. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Effectiveness of Remote Patient Monitoring After Discharge of Hospitalized Patients With Heart Failure: The Better Effectiveness After Transition -- Heart Failure (BEAT-HF) Randomized Clinical Trial.

            It remains unclear whether telemonitoring approaches provide benefits for patients with heart failure (HF) after hospitalization.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial

              Remote patient management in patients with heart failure might help to detect early signs and symptoms of cardiac decompensation, thus enabling a prompt initiation of the appropriate treatment and care before a full manifestation of a heart failure decompensation. We aimed to investigate the efficacy of our remote patient management intervention on mortality and morbidity in a well defined heart failure population.
                Bookmark

                Author and article information

                Contributors
                rohde.le@gmail.com
                felix.ramires@incor.usp.br
                Journal
                ESC Heart Fail
                ESC Heart Fail
                10.1002/(ISSN)2055-5822
                EHF2
                ESC Heart Failure
                John Wiley and Sons Inc. (Hoboken )
                2055-5822
                18 September 2021
                December 2021
                : 8
                : 6 ( doiID: 10.1002/ehf2.v8.6 )
                : 5523-5530
                Affiliations
                [ 1 ] Serviço de Cardiologia, Hospital Moinhos de Vento R. Ramiro Barcelos, 910 ‐ Moinhos de Vento Porto Alegre 90035‐000 Brazil
                [ 2 ] Heart Failure Clinic, Hospital de Clinicas de Porto Alegre and Nursing School, Universidade Federal do Rio Grande do Sul Porto Alegre Brazil
                [ 3 ] Hospital Regional Hans Dieter Schmidt Joinville Brazil
                [ 4 ] Instituto de Cardiologia/ Fundação Universitária de Cardiologia‐ Porto Alegre/RS. Porto Alegre Brazil
                [ 5 ] Hospital Clínico San Carlos Madrid Spain
                [ 6 ] Hospital Ana Nery Salvador Brazil
                [ 7 ] Federal University of Acre Rio Branco Brazil
                [ 8 ] Pronto‐Socorro Cardiológico Universitário de Pernambuco ‐ Prof. Luiz Tavares Recife Brazil
                [ 9 ] Hospital Universitário da Universidade Federal do Maranhão São Luiz Brazil
                [ 10 ] Clínica do Coração de Aracaju Aracaju Brazil
                [ 11 ] Hospital Universitário da Universidade Estadual de Londrina Londrina Brazil
                [ 12 ] Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo Ribeirão Preto Brazil
                [ 13 ] Hospital Naval Marcílio Dias Rio de Janeiro Brazil
                [ 14 ] Hospital Escola Universidade Federal de Pelotas Pelotas Brazil
                [ 15 ] Hospital Universitário de Canoas da Universidade Luterana do Brasil Canoas Brazil
                [ 16 ] Hospital Universitário Pedro Ernesto da Universidade do Estado do Rio de Janeiro Rio de Janeiro Brazil
                [ 17 ] Hospital São Lucas da PUCRS Porto Alegre Brazil
                [ 18 ] Santa Casa de Votuporanga Votuporanga Brazil
                [ 19 ] Hospital das Clínicas da Universidade Federal de Minas Gerais Belo Horizonte Brazil
                [ 20 ] Quanta Diagnóstico por Imagem Curitiba Brazil
                [ 21 ] Instituto D'or de Pesquisa e Ensino (IDOR) and Hospital Cárdio Pulmonar Salvador Brazil
                [ 22 ] Escola Bahiana de Medicina e Saúde Pública Salvador Brazil
                [ 23 ] HCor Research Institute R. Des. Eliseu Guilherme, 147 ‐ Paraíso São Paulo 04004‐030 Brazil
                Author notes
                [*] [* ] Correspondence to: Luis E. Rohde, Serviço de Cardiologia, Hospital Moinhos de Vento, R. Ramiro Barcelos, 910 ‐ Moinhos de Vento, Porto Alegre 90035‐000, Brazil. Email: rohde.le@ 123456gmail.com ; Felix Ramirez, HCor Research Institut, R. Des. Eliseu Guilherme, 147 ‐ Paraíso, São Paulo 04004‐030, Brazil. Email: felix.ramires@ 123456incor.usp.br

                [ † ]

                Luis E. Rohde and Felix Ramirez contributed equally to the study.

                Article
                EHF213516 ESCHF-21-00037
                10.1002/ehf2.13516
                8712788
                34535979
                6cf56067-e707-43b1-b01c-9d7c21ca7b28
                © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 30 May 2021
                : 28 January 2021
                : 05 July 2021
                Page count
                Figures: 2, Tables: 3, Pages: 8, Words: 3438
                Categories
                Study Design
                Study Designs
                Custom metadata
                2.0
                December 2021
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.7.0 mode:remove_FC converted:28.12.2021

                heart failure,natriuretic peptide,telemonitoring
                heart failure, natriuretic peptide, telemonitoring

                Comments

                Comment on this article